PLEASE NOTE: Even though initial research has demonstrated promising results, it is important to note that further clinical studies are needed to fully understand the safety, efficacy, and recommended dosage for BPC 157
R., McCaddon, A., Ahmadi, K
The concern stems from its activation of the VEGFR2 pathway and FAK-paxillin signaling, which drive angiogenesis and are dysregulated in 50% of human cancers (ovarian cancer, melanoma, and colon adenocarcinoma)
Strong or unusual odors indicate bacterial growth
Simply follow the recommended dosage instructions on the product packaging or as advised by your healthcare provider
There are no data to determine when breastfeeding may be safely restarted following administration of CYANOKIT